The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 31, 2006

Filed:

Dec. 07, 2001
Applicants:

Carlo Brugnara, Newton Highlands, MA (US);

Jose Halperin, Brookline, MA (US);

Rudolf Fluckiger, Brookline, MA (US);

Emile M. Bellott, Jr., Beverly, MA (US);

Richard John Lombardy, Littleton, MA (US);

John J. Clifford, Arlington, MA (US);

Ying-duo Gao, Edison, NJ (US);

Reem M. Haidar, Woburn, MA (US);

Eugene W. Kelleher, Medford, MA (US);

Adel M. Moussa, Burlington, MA (US);

Yesh P. Sachdeva, Concord, MA (US);

Minghua Sun, Libertyville, IL (US);

Heather N. Taft, Littleton, MA (US);

Michael H. Zeldin, Cambridge, MA (US);

Inventors:

Carlo Brugnara, Newton Highlands, MA (US);

Jose Halperin, Brookline, MA (US);

Rudolf Fluckiger, Brookline, MA (US);

Emile M. Bellott, Jr., Beverly, MA (US);

Richard John Lombardy, Littleton, MA (US);

John J. Clifford, Arlington, MA (US);

Ying-Duo Gao, Edison, NJ (US);

Reem M. Haidar, Woburn, MA (US);

Eugene W. Kelleher, Medford, MA (US);

Adel M. Moussa, Burlington, MA (US);

Yesh P. Sachdeva, Concord, MA (US);

Minghua Sun, Libertyville, IL (US);

Heather N. Taft, Littleton, MA (US);

Michael H. Zeldin, Cambridge, MA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/55 (2006.01); C07D 233/18 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.


Find Patent Forward Citations

Loading…